Alan S Florjancic

This inventor holds 23 USPTO granted patents and 1 published patent application and 6 EPO patents, primarily in Kinase Inhibitors. Top assignees: Abbott Laboratories Corporation, Abbvie Inc., Other. Active years: 1997-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alan S Florjancic. Retrieved from https://idiyas.com/inventor/alan-s-florjancic

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 1)

% Patents Active = 73.9

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 7.6

ph-index = 4

Forward Citations = 137(Granted Patents)

Location History:

Lake Bluff, IL (US) (1997 - 1999)
Lafayette, CO (US) (2001)
Kenosha, WI (US) (2006 - 2018)

Company Filing History:

11 out of 4,190

Abbott Laboratories Corporation

1 out of 834,601

Other

patents

Years Active: 1997-2018

Loading Chart...

Areas of Expertise:

Kinase Inhibitors

CDK9 Kinase

Cannabinoid Receptor Ligands

Matrix Metalloproteinases

Pyrrolopyridine

Tricyclic Compounds

Amino-Tetrazoles

Antibacterials

Reverse Hydroxamates

Macrocyclic Inhibitors

Biphenyl Hydroxamates

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9957274 - Indane inhibitors of EED and methods of their use (2018-05-01),

2. 9796708 - Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors (2017-10-24),

3. 9346813 - Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors (2016-05-24),

4. 9181246 - Pyrrolopyridine inhibitors of kinases (2015-11-10),

5. 9006275 - Compounds as cannabinoid receptor ligands and uses thereof (2015-04-14),

6. 8841334 - Compounds as cannabinoid receptor ligands and uses thereof (2014-09-23),

7. 8822446 - Pyrrolopyridine inhibitors of kinases (2014-09-02),

8. 8710065 - Tricyclic inhibitors of kinases (2014-04-29),

9. 8546583 - Compounds as cannabinoid receptor ligands and uses thereof (2013-10-01),

10. 8546374 - Amino-tetrazoles analogues and methods of use (2013-10-01),

11. 8435980 - Pyrrolopyridine inhibitors of kinases (2013-05-07),

12. 8383624 - Pyrrolopyrazine inhibitors of kinases (2013-02-26),

13. 8217067 - Amino-tetrazoles analogues and methods of use (2012-07-10),

14. 7875639 - Compounds as cannabinoid receptor ligands and uses thereof (2011-01-25),

15. 7723367 - Amino-tetrazoles analogues and methods of use (2010-05-25),

Title: Alan S. Florjancic: Innovator in Pharmaceutical Chemistry

Introduction

Alan S. Florjancic is a distinguished inventor based in Kenosha, Wisconsin, who has made significant contributions to the field of pharmaceutical chemistry. With an impressive portfolio of 23 patents, he has developed innovative compounds and methods that target various diseases, including cancer.

Latest Patents

Among his latest patents, Florjancic has introduced important advancements such as "Indane Inhibitors of EED and Methods of Their Use." This patent details compounds with a specific structural formula that show potential in treating EED-related conditions, including certain types of cancer. Additionally, he has patented "Pyrrolo [2,3-B] Pyridine CDK9 Kinase Inhibitors," which encompasses compounds for medical compositions that may be used in the treatment of cancer. These inventions reflect his commitment to developing effective therapeutic agents.

Career Highlights

Throughout his career, Alan S. Florjancic has worked with prominent companies, notably Abbott Laboratories Corporation and AbbVie Inc. His experience in these leading organizations has refined his expertise in drug development and innovation related to pharmaceutical applications.

Collaborations

Florjancic has collaborated with notable professionals in his field, including Arturo Perez-Medrano and William A. Carroll. These collaborations have augmented his research and expanded the impact of his innovations in the pharmaceutical industry.

Conclusion

Alan S. Florjancic stands as a key figure in pharmaceutical innovation, with a rich background that includes numerous patents, impactful collaborations, and a stellar career in major pharmaceutical companies. His ongoing work continues to contribute to the development of essential treatments that address significant health challenges.

Profile summary based on public USPTO records.